Continuous-Flow Left Ventricular Assist Device Support in Patients with Ischemic Versus Nonischemic Cardiomyopathy

Brendan P. Chou, BS1; Andre Critsinelis, MD1; Harveen K. Lamba, MD1; Gregory Long, BS1; Andrew B. Civitello, MD1,2; Reynolds M. Delgado, MD1,2; Subhasis Chatterjee, MD3

1 Division of Cardiothoracic Transplantation and Circulatory Support, Baylor College of Medicine, Houston, Texas
2 Department of Cardiopulmonary Transplantation and Center for Cardiac Support, Texas Heart Institute, Houston, Texas
3 Division of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas

To determine whether the cause of cardiomyopathy affects outcomes in patients who undergo continuous-flow left ventricular assist device support, we compared postimplant adverse events and survival between patients with ischemic and nonischemic cardiomyopathy. The inclusion criteria for the ischemic group were a history of myocardial infarction or revascularization (coronary artery bypass grafting or percutaneous coronary intervention), ≥75% stenosis of the left main or proximal left anterior descending coronary artery, or ≥75% stenosis of ≥2 epicardial vessels.

From November 2003 through March 2016, 526 patients underwent device support: 256 (48.7%) in the ischemic group and 270 (51.3%) in the nonischemic group. The ischemic group was older (60.0 vs 50.0 yr), included more men than women (84.0% vs 72.6%), and had more comorbidities. More patients in the nonischemic group were able to have their devices explanted after left ventricular recovery (5.9% vs 2.0%; P = 0.02). More patients in the ischemic group had gastrointestinal bleeding (31.2% vs 22.6%; P = 0.03), particularly from arteriovenous malformations (20.7% vs 11.9%; P = 0.006) and ulcers (16.4% vs 9.3%; P = 0.01). Kaplan-Meier analysis revealed no difference in overall survival between groups (P = 0.24). Older age, previous sternotomy, higher total bilirubin level, and concomitant procedures during device implantation independently predicted death (P ≤ 0.03), whereas cause of heart failure did not (P = 0.08).

Despite the similarity in overall survival between groups, ischemic cardiomyopathy was associated with more frequent gastrointestinal bleeding. This information may help guide the care of patients with ischemic cardiomyopathy who receive continuous-flow left ventricular assist device support. (Tex Heart Inst J 2021;48(4):e207241)

Continuous-flow left ventricular assist devices (LVADs) are used as bridge-to-transplant, bridge-to-recovery, or destination therapy in patients with end-stage heart failure. Since 2006, more than 17,000 continuous-flow LVADs have been implanted, according to the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database, and overall outcomes have improved.1

The causes of advanced heart failure vary greatly;2 and how continuous-flow LVAD support affects outcomes has not been thoroughly explored. Some studies have shown that survival times are shorter in patients with ischemic cardiomyopathy (ICM) than in those with nonischemic cardiomyopathy (NICM); patients with ICM tend to be older and have more comorbidities, widespread atherosclerotic disease, multivessel coronary artery disease, and arrhythmias associated with sudden death.3–4 Other studies have produced conflicting results regarding whether the cause of heart failure is an independent predictor of death after continuous-flow LVAD implantation.5–10 Few investigators have explored the differences between the types and the incidence of postimplant adverse events based on the distinctly different causes of heart failure.

Therefore, the effect of heart failure cause on outcomes in patients who receive continuous-flow LVADs as bridge-to-transplant or destination therapy warrants...
further investigation. In this study, we compared the overall survival and incidence of adverse events after continuous-flow LVAD implantation in patients with ICM versus NICM.

**Patients and Methods**

We performed a single-center retrospective review of all patients who underwent primary implantation of a continuous-flow LVAD—either the HeartMate II (Thoratec, an Abbott company) or the HeartWare HVAD (Medtronic)—from November 2003 through March 2016. Patients were divided into 2 groups on the basis of a standardized definition of ICM developed for clinical research. The criteria for inclusion in the ICM group were a history of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), ≥75% stenosis of the left main or proximal left anterior descending coronary artery, or ≥75% stenosis of ≥2 epicardial vessels. The NICM group included all other patients. The incidence of ICM in the study population was calculated for the periods from 2003 through 2009 and from 2010 through 2016. The Institutional Review Board of CHI St. Luke’s Health–Baylor St. Luke’s Medical Center approved the study (Protocol H38751). The requirement for informed consent was waived because the study was retrospective.

From each patient’s medical record, we documented demographic information, preoperative characteristics including laboratory INTERMACS profile and comorbidities, hemodynamic and echocardiographic data, operative details, postoperative adverse events, and survival outcomes. Severity of valve regurgitation was assessed by color-flow imaging in all cases and quantitatively graded on a 4-point scale (severe = 3, moderate = 2, mild = 1, and none = 0), as documented in the medical record. Operative characteristics included device model (HeartMate II or HeartWare HVAD), cardiopulmonary bypass use and time, aortic cross-clamp use and time, and concomitant procedures performed during the index LVAD implantation. Concomitant procedures included coronary artery bypass grafting, patent foramen ovale closure, and valvular repair or replacement.

Outcome variables included the incidence of postoperative adverse events (including events per patient-year) and overall survival rates through 6 years of follow-up after LVAD implantation. Readmission was defined as a return to the hospital within 30 days of discharge from the index admission. Neurologic dysfunction was defined as a new neurologic deficit associated with abnormal neuroimaging findings and was categorized as either ischemic or hemorrhagic. Patients were considered to have gastrointestinal bleeding if they had one or more of the following: guaiac-positive stool, hematemesis, melena, active bleeding at the time of endoscopy or colonoscopy, or blood in the stomach at the time of endoscopy or colonoscopy. Patients were considered to have an infection if they had one or more of the following: a driveline infection that required surgical treatment, a pump infection that required surgical treatment, or bacteremia (confirmed by positive blood cultures from 2 separate sites). Acute kidney injury within 7 days of LVAD implantation was defined according to the RIFLE (risk, injury, failure, loss of kidney function, and end-stage kidney disease) classification as an abrupt doubling of the serum creatinine level or a 50% reduction in the estimated glomerular filtration rate.

**Statistical Analysis**

Patient demographics, preoperative and operative characteristics, hemodynamic and echocardiographic data, and postoperative adverse events were compared between the 2 groups in a univariate analysis. Continuous variables were reported as mean ± SD. Tests of normality were performed on each variable. Normally distributed variables were compared using the Student t test; variables that were not normally distributed were compared using the Mann-Whitney U test. Categorical variables were reported as number and percentage and were compared using the Pearson χ² test (or the Fisher exact test if expected counts were not sufficiently large). We used χ² analysis to evaluate the difference in the number of patients who had postoperative adverse events.

Overall survival rates in the ICM and NICM groups were compared by using Kaplan-Meier analysis and the log-rank test, with long-term survival defined as 6 years after LVAD implantation. Cox proportional hazards analysis was used to identify independent predictors of mortality. Proportional hazards assumptions were tested by using Schoenfeld residuals. Preoperative and operative variables with P values <0.20 were included in the univariate analysis. Variables with a P value <0.20 in the univariate Cox analysis were included in our final multivariate model. Variables with a variance inflation factor >10 were removed to avoid introducing collinearity. Heart failure cause was forced into our model. P values <0.05 were considered statistically significant. All analyses were performed with SPSS, version 20 (SPSS, an IBM company).

**Results**

A total of 526 patients underwent primary implantation of a continuous-flow LVAD during the study period, including the HeartMate II in 403 (76.6%) and the HeartWare HVAD in 123 (23.4%). The ICM group included 256 patients (48.7%); the NICM group, 270 (51.3%) (Table I). From 2003 through 2009, 52 patients (43.7%) had ICM; from 2010 through 2016, 204 (50.1%) had ICM (P=0.22).
| Variable                                      | Ischemic Cardiomyopathy (n=256) | Nonischemic Cardiomyopathy (n=270) | P Value |
|----------------------------------------------|---------------------------------|------------------------------------|---------|
| Age (yr)                                     | 60.0 ± 9.8                      | 50.0 ± 14.7                        | <0.001  |
| Male                                         | 215 (84.0)                      | 196 (72.6)                         | 0.002   |
| Body mass index*                             | 27.4 ± 5.9                      | 28.9 ± 7.3                         | 0.27    |
| Tobacco use                                  | 127 (49.6)                      | 92 (34.1)                          | <0.001  |
| Medical history                              |                                 |                                    |         |
| Hypertension                                 | 177 (69.1)                      | 142 (52.6)                         | <0.001  |
| Diabetes                                     | 135 (52.7)                      | 97 (35.9)                          | <0.001  |
| Chronic obstructive pulmonary disease         | 42 (16.4)                       | 32 (11.9)                          | 0.13    |
| Peripheral vascular disease                  | 16 (6.3)                        | 5 (1.9)                            | 0.005   |
| Stroke                                       | 32 (12.5)                       | 41 (15.2)                          | 0.36    |
| Severe valvular regurgitation                |                                 |                                    |         |
| Mitral                                       | 46 (18.0)                       | 62 (23.0)                          | 0.16    |
| Aortic                                       | 5 (2.0)                         | 1 (0.4)                            | 0.10    |
| Tricuspid                                    | 24 (9.4)                        | 35 (13.0)                          | 0.19    |
| Previous sternotomy                          | 127 (49.6)                      | 46 (17.0)                          | <0.001  |
| Mechanical circulatory support**             | 138 (53.9)                      | 131 (48.5)                         | 0.22    |
| INTERMACS profile                            | —                               | —                                  | 0.77    |
| 1                                            | 40 (15.6)                       | 35 (13.0)                          | —       |
| 2                                            | 88 (34.4)                       | 85 (31.5)                          | —       |
| 3                                            | 91 (35.5)                       | 109 (40.4)                         | —       |
| 4                                            | 26 (10.2)                       | 29 (10.7)                          | —       |
| 5+                                           | 11 (4.3)                        | 12 (4.4)                           | —       |
| Laboratory values                            |                                 |                                    |         |
| Hemoglobin (g/dL)                            | 11.4 ± 2.1                      | 11.6 ± 2.2                         | 0.26    |
| White blood cell count (× 10³/µL)            | 9.6 ± 4.3                       | 9.1 ± 5.0                          | 0.21    |
| Platelets (× 10³/µL)                         | 208.0 ± 93.1                    | 205.0 ± 94.1                       | 0.71    |
| Sodium (mEq/L)                               | 135.2 ± 4.6                     | 135.0 ± 4.5                        | 0.52    |
| Creatinine (mg/dL)                           | 1.5 ± 0.8                       | 1.4 ± 0.7                          | 0.31    |
| Blood urea nitrogen (mg/dL)                  | 29.0 (19.8–40.0)                | 24.0 (18.0–34.0)                   | 0.002   |
| Aspartate aminotransferase (U/L)             | 37.5 (26.8–68.0)                | 36.5 (25–56.8)                     | 0.009   |
| Alanine aminotransferase (U/L)               | 30.0 (21.0–56.0)                | 30.0 (20.0–53.0)                   | 0.12    |
| Total bilirubin (mg/dL)                      | 1.0 (0.6–1.6)                   | 1.2 (0.7–1.9)                      | 0.12    |
| International normalized ratio               | 1.3 ± 0.6                       | 1.2 ± 0.4                          | 0.20    |
| Hemodynamic and echocardiographic data       |                                 |                                    |         |
| Cardiac output (L/min/m²)                    | 3.5 ± 1.6                       | 3.3 ± 1.5                          | 0.09    |
| Central venous pressure (mmHg)               | 11.8 ± 7.3                      | 11.7 ± 7.7                         | 0.82    |
| Left ventricular end-diastolic diameter (cm) | 6.3 ± 1.0                       | 6.8 ± 1.1                          | 0.52    |
| Mean pulmonary artery pressure (mmHg)        | 35.7 ± 10.5                     | 35.7 ± 11.6                        | 0.99    |
| Pulmonary capillary wedge pressure (mmHg)    | 24.5 ± 10.0                     | 25.1 ± 10.4                        | 0.51    |
| Operative details                            |                                 |                                    |         |
| Device model                                 |                                 |                                    |         |
| HeartMate II                                 | 193 (75.4)                      | 210 (77.8)                         | 0.87    |
| HeartWare HVAD                               | 63 (24.6)                       | 60 (22.2)                          | 0.87    |
| Cardiopulmonary bypass use                   | 249 (97.3)                      | 254 (94.1)                         | 0.07    |
| Cardiopulmonary bypass time (min)            | 91.6 ± 55.1                     | 79.7 ± 51.8                        | 0.09    |
| Aortic cross-clamp use                       | 24 (9.4)                        | 26 (9.6)                           | 0.92    |
| Aortic cross-clamp time (min)                | 4.3 ± 17.3                      | 5.2 ± 21.2                         | 0.61    |
| Concomitant procedures                       | 96 (37.5)                       | 84 (31.1)                          | 0.12    |
| Valve repair/replacement                     |                                |                                    |         |
| Aortic                                       | 12 (4.7)                        | 10 (3.7)                           | 0.87    |
| Mitral                                       | 26 (10.2)                       | 32 (11.9)                          | 0.49    |
| Tricuspid                                    | 18 (7.0)                        | 21 (7.8)                           | 0.87    |

INTERMACS = Interagency Registry for Mechanically Assisted Circulatory Support
* Calculated as weight in kilograms divided by height in meters squared
** Use of temporary ventricular assist device, intra-aortic balloon pump, Impella heart pump (Abiomed, Inc.), or extracorporeal membrane oxygenation

Data are shown as mean ± SD, as number and percentage, or as median and interquartile range. P <0.05 was considered statistically significant.
The mean age of the ICM group was significantly greater than that of the NICM group, and the ICM group included a larger percentage of men, as well as smokers. Before LVAD implant, more of the ICM patients had hypertension, diabetes, peripheral vascular disease, and previous sternotomy. The ICM group also had significantly higher mean levels of blood urea nitrogen and aspartate aminotransferase. The groups were similar in terms of the percentage of patients who were bridged to transplant \((P = 0.45)\), preoperative complete blood count, hemodynamic measurements, and distribution of INTERMACS profiles. Operatively, the groups were similar in terms of cardiopulmonary bypass use, cardiopulmonary bypass time, aortic cross-clamp use, and aortic cross-clamp time.

Of the 270 patients in the NICM group, 190 (70.4%) had idiopathic NICM (Table II). Among the remaining patients with NICM, the most common causes were viral myocarditis in 20 (7.4%), familial dilated cardiomyopathy in 16 (5.9%), valvular dysfunction in 12 (4.4%), and doxorubicin toxicity in 9 (3.3%).

The postoperative outcomes in both groups were largely similar. However, 16 patients (5.9%) in the NICM group recovered LV function to the extent that the LVAD could be explanted, compared with 5 patients (2.0%) in the ICM group \((P = 0.02)\) (Table III). The ICM group had greater percentages of patients who were bridged to transplant (20.7% vs 17.0%), continued receiving LVAD support (32.8% vs 33.7%), or died (39.1% vs 35.2%).

In our analysis of postoperative adverse events, the 2 groups had similar rates of neurologic dysfunction, infection, acute kidney injury, and 30-day readmission (Table IV). Gastrointestinal bleeding was more frequent in the ICM group (31.3%) than in the NICM group (26.6%) \((P = 0.03)\). To better characterize these events, we evaluated the site and cause of bleeding in each event (Table V). Notably, the ICM group had higher rates of bleeding in both the upper (28.1% vs 18.1%; \(P = 0.007\)) and lower (23.0% vs 13.3%; \(P = 0.004\)) gastrointestinal tracts. In particular, the ICM group had higher rates of gastrointestinal bleeding in the small intestine (4.7% vs 1.5%; \(P = 0.03\)) and colon (10.2% vs 5.6%; \(P = 0.049\)). The ICM group also had higher rates of gastrointestinal bleeding from arteriovenous malformations (20.7% vs 11.9%; \(P = 0.006\)) and ulcers (16.4% vs 9.3%; \(P = 0.01\)).

The ICM group also had a higher rate of diverticulosis (5.9% vs 3.3%), but this difference was not statistically significant \((P = 0.17)\).

Finally, Kaplan-Meier analysis revealed that overall survival did not differ between the ICM and NICM groups \((P = 0.24)\), log-rank) (Fig. 1). Furthermore, multivariate Cox proportional hazards analysis revealed that the cause of heart failure was not an independent predictor of death \((P = 0.08)\) (Table VI). Significant independent predictors included older age \((P < 0.001)\), total bilirubin level \((P = 0.001)\), previous sternotomy \((P = 0.03)\), and concomitant procedures during LVAD implantation \((P = 0.048)\).

### Discussion

In this study, we found that the cause of heart failure did not independently predict long-term survival after continuous-flow LVAD implantation. However, we also found that gastrointestinal bleeding, particularly from arteriovenous malformations and ulcers, occurred significantly more often in the ICM group \((P = 0.03)\). Multivariate Cox proportional hazards analysis showed that older age, previous sternotomy, total bilirubin level, and concomitant procedures during LVAD implantation were independent predictors of death. In addition, the mortality rate was higher for patients with ICM.

---

**TABLE II. Causes of Nonischemic Cardiomyopathy in 270 Patients**

| Cause                              | No. (%) |
|-----------------------------------|---------|
| Idiopathic                        | 190 (70.4) |
| Viral myocarditis                 | 20 (7.4) |
| Familial dilated cardiomyopathy   | 16 (5.9) |
| Valvular dysfunction              | 12 (4.4) |
| Doxorubicin exposure              | 9 (3.3)  |
| Left ventricular noncompaction     | 5 (1.9)  |
| Peripartum cardiomyopathy         | 4 (1.5)  |
| Alcohol use                       | 4 (1.5)  |
| Sarcoidosis                       | 3 (1.1)  |
| Hypertension                      | 2 (0.7)  |
| Amyloidosis                       | 1 (0.4)  |
| Chagas disease                    | 1 (0.4)  |
| Cocaine use                       | 1 (0.4)  |
| Congenital malformation           | 1 (0.4)  |
| Scleroderma                       | 1 (0.4)  |

---

**TABLE III. Postoperative Outcomes**

| Outcome                  | ICM \((n=256)\) | NICM \((n=270)\) | \(P\) Value |
|--------------------------|-----------------|-----------------|-------------|
| Transplant               | 53 (20.7)       | 46 (17.0)       | 0.28        |
| Continued LVAD support   | 84 (32.8)       | 91 (33.7)       | 0.83        |
| LVAD explant             | 5 (2.0)         | 16 (5.9)        | 0.02        |
| Death                    | 100 (39.1)      | 95 (35.2)       | 0.36        |
| Loss to follow-up        | 13 (5.1)        | 20 (7.4)        | 0.27        |

ICM = ischemic cardiomyopathy; LVAD = left ventricular assist device; NICM = nonischemic cardiomyopathy

Data are shown as number and percentage. \(P < 0.05\) (Pearson \(\chi^2\) test) was considered statistically significant.
The overall incidence of ICM in our study population (50.1%) was comparable to that among the 3,511 patients in the Nationwide Inpatient Sample database who had an LVAD implanted in the period from 2011 through 2014 (53.5%).

Larger studies of this difference are warranted.

The patients with ICM also had fewer comorbidities (for example, tobacco use, peripheral vascular disease, diabetes mellitus, and hypertension). This finding was expected because these comorbidities are risk factors for the development of ICM.

### TABLE IV. Postoperative Adverse Events

| Adverse Event                  | ICM (n=256) | NICM (n=270) |
|-------------------------------|-------------|-------------|
|                               | No. of Patients (%) | No. of Events | Events/Pt-Yr | No. of Patients (%) | No. of Events | Events/Pt-Yr | P Value |
| Neurologic dysfunction        | 73 (28.5)   | 101          | 0.237        | 68 (25.2)     | 91           | 0.169        | 0.43    |
| Ischemic                      | 43 (16.8)   | 55           | 0.129        | 39 (14.4)     | 44           | 0.082        | 0.46    |
| Hemorrhagic                   | 43 (16.8)   | 46           | 0.108        | 42 (15.6)     | 47           | 0.087        | 0.70    |
| Infection                     | 91 (35.5)   | 236          | 0.555        | 103 (38.1)    | 297          | 0.550        | 0.54    |
| Pump                          | 13 (5.1)    | 24           | 0.056        | 19 (7.0)      | 36           | 0.067        | 0.35    |
| Driveline                     | 21 (8.2)    | 42           | 0.099        | 34 (12.6)     | 73           | 0.135        | 0.10    |
| Bacteremia                    | 83 (32.4)   | 170          | 0.400        | 83 (30.7)     | 188          | 0.349        | 0.68    |
| Gastrointestinal bleeding     | 80 (31.3)   | 131          | 0.308        | 61 (22.6)     | 85           | 0.158        | 0.03    |
| Acute kidney injury           | 103 (40.2)  | —            | —            | 105 (38.9)    | —            | —            | 0.55    |
| 30-day readmission            | 54 (21.1)   | —            | —            | 46 (17.0)     | —            | —            | 0.24    |

Pt-Yr = patient-year

$P<0.05$ ($\chi^2$ test) was considered statistically significant.

### TABLE V. Gastrointestinal Bleeding Characteristics

| Characteristic               | ICM (n=256) | NICM (n=270) |
|-----------------------------|-------------|-------------|
| Anatomic site               |             |             |
| Upper GI tract              | 72 (28.1)   | 49 (18.1)   | 0.007     |
| Esophagus                   | 7 (2.7)     | 2 (0.7)     | 0.08      |
| Stomach                     | 48 (18.8)   | 35 (13.0)   | 0.07      |
| Duodenum                    | 15 (5.9)    | 7 (2.6)     | 0.06      |
| NOS                         | 2 (0.8)     | 5 (1.9)     | 0.28      |
| Lower GI tract              | 59 (23.0)   | 36 (13.3)   | 0.004     |
| Jejunum                     | 10 (3.9)    | 9 (3.3)     | 0.72      |
| Small intestine–NOS         | 12 (4.7)    | 4 (1.5)     | 0.03      |
| Colon                       | 26 (10.2)   | 15 (5.6)    | 0.049     |
| Rectum                      | 5 (2.0)     | 4 (1.5)     | 0.68      |
| NOS                         | 6 (2.3)     | 4 (1.5)     | 0.47      |
| Cause                       |             |             |
| AV malformation             | 53 (20.7)   | 32 (11.9)   | 0.006     |
| Ulcer                       | 42 (16.4)   | 25 (9.3)    | 0.01      |
| Diverticulosis              | 15 (5.9)    | 9 (3.3)     | 0.17      |
| Polyp                       | 3 (1.2)     | 4 (1.5)     | 0.76      |
| M-W syndrome                | 2 (0.8)     | 1 (0.4)     | 0.53      |
| Unknown                     | 15 (5.9)    | 16 (5.9)    | 0.97      |

AV = arteriovenous; GI = gastrointestinal; ICM = ischemic cardiomyopathy; M-W = Mallory-Weiss; NICM = nonischemic cardiomyopathy; NOS = not otherwise specified

Data are shown as number and percentage. $P<0.05$ was considered statistically significant.

---

**Fig. 1** Graph shows Kaplan-Meier estimates of overall survival after left ventricular assist device implantation in patients with either ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM).
of patients with ICM had undergone a previous sternotomy, typically for coronary artery bypass grafting. (In the NICM group, previous sternotomy was typically for valvular repairs and replacements to treat valvular cardiomyopathy). Although viral and familial dilated cardiomyopathy and valvular disease were common causes of heart failure in our NICM cohort, by far the most frequent cause was idiopathic (70.4%). This was not unusual because the cause of NICM remains unknown in many cases; regardless of the cause of chronic end-stage heart failure, invasive and costly diagnostic studies are usually not warranted in patients who are being considered for LVAD support because the results will not alter their care and management. The rarest causes in our NICM cohort were related to exposure to chemotherapeutic agents (for example, doxorubicin), peripartum cardiomyopathy, alcohol and cocaine use, viral infection or Chagas disease, and congenital disorders (for example, left ventricular noncompaction and congenital malformation).

A significantly greater percentage of NICM patients than ICM patients recovered LV function to the extent that they could have their LVADs explanted ($P=0.02$). This finding concurs with an analysis by Goldstein and colleagues, who concluded that LV recovery is more likely in young patients with NICM. Studies of myocardial response to LVAD therapy have shown that LV unloading may improve cardiomyocyte contractile function and normalize LV geometry and neurohormonal function.$^{19-21}$ Other studies suggest that reverse remodeling is less likely in patients with ICM, perhaps because of chronic and irreversible scarring after myocardial infarction, which may hamper recovery.$^{18,22,23}$

Of the NICM causes analyzed in this study, several are acute and may be more reversible and prone to reverse remodeling (although this may apply only to certain causes such as viral and postpartum cardiomyopathy). In contrast, some types of chronic NICM (those with hereditary or valvular causes, for example) may resist reverse remodeling and recovery. Additional studies are warranted to understand fully the optimal conditions for reverse remodeling and the best timing for bridge-to-recovery strategies.

An unexpected and interesting finding was that postoperative gastrointestinal bleeding, particularly from arteriovenous malformations and ulcers, was more common in patients with ICM than in those with NICM. In our study, age at implantation may have contributed to this difference. This is consistent with the suggestion by Kawabori and associates,$^{24}$ that age at implantation is the primary predictor of postoperative gastrointestinal bleeding. Of note, we also saw an increase over time in the proportion of LVAD recipients with ICM—from 43.7% (2003–2009) to 50.1% (2010–2016) ($P=0.22$).

The association of gastrointestinal bleeding from arteriovenous malformations with nonpulsatile flow and anticoagulation has been established.$^{24-26}$ One theory is that the aortic stenosis effectively caused by axial flow prevents aortic valve opening and increases the shear stress caused by the pump, leading to acquired von Willebrand disease.$^{27}$ Other studies suggest that reduced pulsatility reduces intestinal mucosal perfusion, causing ischemia and formation of friable new vessels.$^{28}$ A recently proposed theory, related to the pathophysiology of arteriovenous malformation–related bleeding in continuous-flow LVAD recipients, is that angiodysplasia may be part of the natural pathophysiology of advanced heart failure. Patel and colleagues$^{29}$ reported a significantly higher prevalence of angiodysplasia ($P=0.009$) in patients with advanced heart failure than in a control group. Clinically, our findings suggest that gastrointestinal bleeding may be encountered more frequently in LVAD recipients as the proportion of those who are older and have ICM grows. Consequently, our results warrant wider investigation to identify preventive strategies to reduce the incidence of such bleeding in this patient population.

**Limitations**

Our study had several limitations. First, it was a nonrandomized, retrospective, single-institution study and therefore inherently limited by its design. Second, the cause of the cardiomyopathy in most of our NICM patients was unknown, which may have confounded our results. Last, our classifications of heart failure causes in this study may not mirror the various classifications that have been used in other studies on this topic.

**Conclusions**

We investigated postimplant complications and long-term survival in patients with ICM or NICM who underwent continuous-flow LVAD support. The cause of heart failure was not a significant independent predictor of survival after continuous-flow LVAD implantation.

### TABLE VI. Multivariate Cox Proportional Hazards Analysis of Mortality

| Variable            | HR     | 95% CI     | P Value |
|---------------------|--------|------------|---------|
| Age                 | 1.03   | 1.01–1.04  | <0.001  |
| Total bilirubin     | 1.06   | 1.02–1.11  | 0.001   |
| Previous sternotomy | 1.30   | 1.04–1.87  | 0.03    |
| Concomitant procedures | 1.08   | 1.00–1.75  | 0.048   |
| Heart failure cause | 1.32   | 0.97–1.77  | 0.08    |
| BUN                 | 1.01   | 1.00–1.01  | 0.08    |
| INR                 | 1.15   | 0.88–1.49  | 0.31    |

BUN = blood urea nitrogen; HR = hazard ratio; ICM = ischemic cardiomyopathy; INR = international normalized ratio

$P<0.05$ was considered statistically significant.
(HR=1.32; P=0.08), and patients with ICM were more likely to have gastrointestinal bleeding, particularly from arteriovenous malformations and ulcers.

Acknowledgment

Jeanie F. Woodruff, BS, ELS, of the Scientific Publications & Grants department at the Texas Heart Institute, contributed to the editing of the manuscript.

Published: 1 September 2021

Conflict of interest disclosure: Dr. Lamba has received funding from Medtronic Inc.

References

1. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant 2017;36(10):1080-6.
2. Ziaieb A, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13(6):368-78.
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality or morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA 1995;274(6):616]. JAMA 1995;273(18):1450-6.
4. Holt KE, Parkhill J, Mazzoni CJ, Roumagru P, Well FX, Goodhead I, et al. High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi. Nat Genet 2008;40(8):987-93.
5. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987;59(6):634-8.
6. Ng ACC, Sindone AP, Wong HSP, Freedman SB. Differences in management and outcome of ischemic and non-ischemic cardiomyopathy. Int J Cardiol 2008;129(2):198-204.
7. Nony P, Boiselle JP, Girard P, Leizorovicz A, Lieve M, Chifflet R. Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure. Eur Heart J 1999;21(3):1101-8.
8. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Packer M, Adamopoulos S, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362(9377):7-13.
9. Asebaker H, Subahi A, Adegbalab O, Yassin AS, Akintoye E, Abdurahman A, et al. Comparison of in-hospital outcomes of patients with-versus-without ischemic cardiomyopathy undergoing left ventricular assist device placement. Am J Cardiol 2019;123(3):414-8.
10. Kumar S, Ward C, Taghavi S, Wilson L, Mangi AA. Outcomes of LVAD insertion in ischemic vs non-ischemic cardiomyopathy patients [abstract]. J Card Fail 2012;18(8):S44.
11. Tsiouris A, Borgi J, Karam J, Nemeh HW, Paone G, Brewer RJ, Morgan JA. Ischemic versus nonischemic dilated cardiomyopathy: the implications of heart failure etiology on left ventricular assist device outcomes. ASAIO J 2013;59(2):130-5.
12. Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39(2):210-8.
13. Stevenson LW, Tillisch JH, Hamilton M, Luu M, Chelimsky-Fallick C, Moriguchi J, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990;66(19):1348-54.
14. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16(7):777-802.
15. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8(4):R204-12.
16. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356(8):830-40.
17. Hazenbos M, Dennert R, Heymans S. Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Neth Heart J 2012;20(7-8):323-5.
18. Goldstein DJ, Maybaum S, MacGillivray TE, Moore SA, Bogaev R, Farrar DJ, et al. Young patients with nonischemic cardiomyopathy have higher likelihood of left ventricular recovery during left ventricular assist device support. J Card Fail 2012;18(5):392-5.
19. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355(18):1873-84.
20. Bruggink AH, van Oosterhout MFM, de Jonge N, Ivangh B, van Kuik J, Voorbij RHAM, et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006;25(9):1091-8.
21. Heerdt PM, Holmes JW, Cat B, Barbone A, Madigan JD, Reiken S, et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 2004;100(22):2713-9.
22. Wever-Pinzon J, Selzmann CH, Stoddard G, Wever-Pinzon O, Catino A, Kfouri AG, et al. Impact of ischemic heart failure etiology on cardiac recovery during mechanical unloading. J Am Coll Cardiol 2016;68(16):1741-52.
23. Mano A, Nakatani T, Oda N, Kato T, Niwaya K, Tagusari O, et al. Which factors predict the recovery of natural heart function after insertion of a left ventricular assist system? J Heart Lung Transplant 2008;27(8):869-74.
24. Kawabori M, Kurihara C, Critesenlis AC, Sugura T, Kaku Y, Civitello AB, et al. Gastrointestinal bleeding after HeartMate II or HVAD implantation: incidence, location, etiology, and effect on survival. ASAIO J 2020;66(3):283-90.
25. Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 2005;24(1):105-9.
26. Demiroz ZT, Radovanovic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011;30(8):849-53.
27. Nascimbene A, Neelamegham S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 2016;127(25):3133-41.
28. Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013;6(3):517-26.
29. Patel SR, Vukelic S, Kwah J, Chinnadurai T, Saeed O, Goldstein D, Jorde UP. Gastrointestinal angiodysplasia is part of the vascular pathophysiology of advanced heart failure [abstract]. J Heart Lung Transplant 2019;38(4):S136-7.